Close Menu

NEW YORK – Natera said after the close of the market on Wednesday that its first quarter revenues increased 41 percent over Q1 2019.

Last month, the company said it expected a 35 percent year-over-year increase in revenues for the quarter.

For the quarter ended March 31, Natera reported $94 million in revenues, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.